MedPath

Tenamfetamine

Generic Name
Tenamfetamine
Drug Type
Small Molecule
Chemical Formula
C10H13NO2
CAS Number
4764-17-4
Unique Ingredient Identifier
XJZ28FJ27W
Background

An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]

Clinical Trials
Related News

HHS Approves Mandatory Fentanyl Testing for Truck Drivers Starting July 2024

• The U.S. Department of Health and Human Services has authorized testing for fentanyl in federally regulated occupations, including truck drivers, through both urine and oral fluid drug panels effective July 2024. • Data from motor carriers performing hair follicle testing revealed 137 fentanyl positives in 2023, with 56% being fentanyl-only cases, demonstrating the growing concern of fentanyl use in the transportation industry. • The synthetic opioid, approximately 100 times more potent than morphine, has become the third most frequently identified drug in U.S. testing, accounting for 13.81% of all drugs reported by forensic laboratories.

Eculizumab Shows Promise in Treating Thymoma-Associated Myasthenia Gravis

• A real-world study demonstrates that eculizumab significantly reduces Myasthenia Gravis Activities of Daily Living (MG-ADL) scores in patients with thymoma-associated myasthenia gravis. • The research indicates a substantial decrease in the need for corticosteroids among patients treated with eculizumab by week 12. • Clinically meaningful improvements were observed in 81.8% of patients, with initial benefits appearing within an average of 1.7 weeks after starting eculizumab. • The study suggests eculizumab is a safe and effective treatment option for this severe myasthenia gravis subtype, warranting further investigation through larger randomized controlled trials.

Nipocalimab Receives FDA Priority Review for Generalized Myasthenia Gravis Treatment

• The FDA granted Priority Review to nipocalimab for treating gMG in antibody-positive patients, expediting its potential availability to patients. • Phase 3 Vivacity-MG3 study results supported the application, demonstrating sustained disease control and significant MG-ADL score reduction. • Nipocalimab, a monoclonal antibody, aims to reduce IgG autoantibodies, addressing the underlying cause of gMG without broad immunosuppression. • Johnson & Johnson also submitted a Marketing Authorisation Application to the EMA, seeking approval of nipocalimab in gMG in Europe.

HEALEY ALS Platform Trial: Streamlining Drug Development for Amyotrophic Lateral Sclerosis

• The HEALEY ALS Platform Trial is pioneering a new approach to accelerate the development of effective treatments for amyotrophic lateral sclerosis (ALS). • By testing multiple drugs simultaneously using a shared infrastructure, the platform trial significantly reduces the time and cost associated with traditional clinical trials. • Initial results from the platform have led to two drugs, CNM-Au8 and pridopidine, advancing to Phase 3 testing based on promising trends in secondary outcome measures and biomarker data. • The collaborative effort unites patients, clinicians, scientists, and industry partners, fostering innovation and improving access to care across a network of over 70 sites.

Postbiotic Supplementation Shows Promise in Reducing Inflammation and Pneumonia Risk in Stroke Patients

• A randomized controlled trial reveals that postbiotic supplementation significantly reduces inflammation and oxidative stress in patients with cerebrovascular accident (CVA). • The study found a notable decrease in serum IL-1beta, MDA, and Hs-CRP levels, along with an increase in TAC levels, indicating improved antioxidant capacity. • Postbiotic supplementation was associated with a significantly lower incidence of pneumonia among CVA patients in the ICU, suggesting a potential protective effect. • The intervention improved SOFA scores, suggesting a role in mitigating organ dysfunction, though other clinical outcomes like NIHSS and APACHE II scores were not significantly affected.

Scholar Rock's Apitegromab Shows Clinically Meaningful Improvement in Phase 3 SMA Trial

• Scholar Rock's apitegromab met its primary endpoint in the Phase 3 SAPPHIRE trial, demonstrating statistically significant improvement in motor function for SMA patients. • The trial showed a 1.8-point improvement in motor function compared to placebo, as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE). • Scholar Rock plans to submit regulatory applications to the FDA and EMA in Q1 2025, potentially launching the drug in the US by Q4 2025. • Apitegromab was well-tolerated, with a safety profile consistent with previous studies, and 98% of patients enrolled in an open-label extension study.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy